Sangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Sangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
February 23, 2018 8:58 AM EST
Jefferies raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $33.00 (from $18.00) while maintaining a Buy rating.
...
More
February 22, 2018 4:26 PM EST
Piper Jaffray raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $32.00 (from $25.00) while maintaining a Overweight rating.
...
More
February 22, 2018 12:23 PM EST
Wells Fargo raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $39.00 (from $30.00) while maintaining a Outperform rating.
The analyst likes the company's competitive advantage in gene-editing, which is attributed to years of experience with single loci targeting and suspects it should be... More
February 22, 2018 11:56 AM EST
Barclays raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $30.00 (from $20.00) while maintaining a Overweight rating.
Analyst Gena Wang ups the price target to reflect technology capabilities at the company and progress in clinical programs. The analyst says the with... More
February 22, 2018 7:22 AM EST
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
...
More
